专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

US07534572B2 Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue 有权
公开(公告)号：US07534572B2
公开(公告)日：2009-05-19
申请号：US10627631
申请日：2003-07-28
申请人： Marc Achen , Steven Stacker
发明人： Marc Achen , Steven Stacker
IPC分类号： G01N33/53 , G01N33/559 , G01N33/561 , G01N33/574 , G01N33/577 , C12P21/08
CPC分类号： A61K38/1866 , A61K2039/505 , C07K16/22 , C07K16/24 , G01N33/57484 , G01N2333/475 , G01N2333/52
摘要： A method for treating and alleviating disease characterized by the expression of VEGF-D involving screening to find an organism with tumor cells expressing VEGF-D and administering an effective amount of a VEGF-D antagonist; a method for screening for neoplastic diseas, where detection of VEGF-D on or in a sample such as tumor cells, blood vessel endothelial cells or lymph vessel endothelial cells indicates neoplastic disease; a method for promoting and maintaining vascularization of normal tissue in an organism involving administering a vascularization promoting amount of VEGF-D or a fragment or analog thereof to the organism; a method for screening tumors for metastatic risk involving detecting expression of VEFG-D by a tumor which indicates metastatic risk; and a method of detecting micro-metastasis of neoplastic disease involving detection of VEGF-D on or in a tissue sample which indicates metastasis of a neoplastic disease.

82. 发明授权

US07511012B2 Myostatin binding agents 失效
公开(公告)号：US07511012B2
公开(公告)日：2009-03-31
申请号：US10742379
申请日：2003-12-19
申请人： Hq Han , Hosung Min , Thomas Charles Boone
发明人： Hq Han , Hosung Min , Thomas Charles Boone
IPC分类号： A61K38/03 , A61K38/04 , A61K38/02 , A61K38/08 , A61K38/10 , A61K38/16 , C07K19/00 , C07K16/00 , C07K16/22 , C07K14/00
CPC分类号： C07K16/22 , A61K38/00 , A61K2039/505 , C07K14/00 , C07K14/475 , C07K2317/21 , C07K2317/94 , C07K2319/00 , C07K2319/30 , C07K2319/35 , C12N2710/14143 , G01N33/567 , G01N33/74 , G01N2333/475
摘要： The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.

83. 发明申请

US20080311601A1 Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy 审中-公开
标题翻译：癌症预测与预后方法及癌症治疗监测方法
公开(公告)号：US20080311601A1
公开(公告)日：2008-12-18
申请号：US12091889
申请日：2006-11-01
申请人： James J. Elting , Walter P. Carney , Peter J. Hamer , Douglas Bigwood
发明人： James J. Elting , Walter P. Carney , Peter J. Hamer , Douglas Bigwood
IPC分类号： G01N33/574 , C12Q1/02
CPC分类号： G01N33/57492 , G01N2333/475 , G01N2333/71 , G01N2800/52
摘要： The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF as a biomarker for multi-kinase inhibitors.
摘要翻译：本发明涉及生物标志物和生物标志物用于癌症的预测和预后以及使用生物标志物来监测癌症治疗的功效的用途。具体地，本发明涉及VEGF作为多激酶抑制剂的生物标志物的用途。

84. 发明授权

US07465551B2 Method of determining cytokine dosage for improving myelosuppressive state 有权
标题翻译：确定改善骨髓抑制状态的细胞因子用量的方法
公开(公告)号：US07465551B2
公开(公告)日：2008-12-16
申请号：US11500186
申请日：2006-08-07
申请人： Rosalyn D. Blumenthal , David M. Goldenberg
发明人： Rosalyn D. Blumenthal , David M. Goldenberg
IPC分类号： G01N33/53 , G01N33/567 , A61K38/19
CPC分类号： G01N33/6863 , G01N33/57488 , G01N2333/475 , G01N2800/24
摘要： The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose. Measured levels of one or more cytokines in a patient subjected to cytotoxic therapy, relative to a normal population, may be used to determine the dose of a hematopoietic cytokine to be administered to the patient.
摘要翻译：本发明提供了用于评估患者骨髓抑制状态的试剂盒和方法。这些方法和试剂盒为细胞毒性和骨髓抑制治疗提供了有用的辅助物质。通过建立某些细胞因子的阈值水平作为骨髓抑制的替代物，治疗方案可以优化，以减少骨髓毒性，同时最大化有效剂量。相对于正常群体，进行细胞毒性治疗的患者中的一种或多种细胞因子的测量水平可用于确定待给予患者的造血细胞因子的剂量。

85. 发明申请

US20080286811A1 Cyr61 as a Biomarker for Diagnosis and Prognosis of Cancers of Epithelial Origin 有权
标题翻译： Cyr61作为上皮源性癌症诊断和预后的生物标志物
公开(公告)号：US20080286811A1
公开(公告)日：2008-11-20
申请号：US11815831
申请日：2006-02-17
申请人： Marsha A. Moses , Bo Zhang
发明人： Marsha A. Moses , Bo Zhang
IPC分类号： G01N33/53 , G01N33/48 , G01N33/566
CPC分类号： G01N33/57484 , G01N2333/475
摘要： Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient.
摘要翻译：尿Cyr61蛋白水平在具有上皮起源癌，即乳腺癌和卵巢癌的患者中上调。因此，本发明涉及用于预后评价和诊断上皮癌的癌症的方法。此外，尿样中检测到的Cyr61蛋白的量与疾病状态相关，使得Cyr61水平可用于预测癌症的存在和转移潜能。因此，测量尿液中Cyr61的水平提供了一种快速，简便和安全的屏幕，可用于诊断和预测患者的癌症。

86. 发明申请

US20080227119A1 ELISA for VEGF 审中-公开
标题翻译： VEGF的ELISA
公开(公告)号：US20080227119A1
公开(公告)日：2008-09-18
申请号：US11866560
申请日：2007-10-03
申请人： Yu-Ju G. Meng , Kyu H. Hong , Johnny Gutierrez
发明人： Yu-Ju G. Meng , Kyu H. Hong , Johnny Gutierrez
IPC分类号： G01N33/53 , C07K16/18 , C12N5/06
CPC分类号： G01N33/57496 , C07K16/22 , G01N33/74 , G01N2333/475
摘要： The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.
摘要翻译：患者血液或其他生物样品中的血管内皮生长因子（VEGF）活性可作为癌症，糖尿病，心脏病和其他病理学的诊断和预后指标。提供抗体夹心ELISA方法和VEGF作为抗原的试剂盒，以检测来自动物模型和人类患者的生物样品中VEGF水平的类型，并可用作诊断/预后指标。

87. 发明申请

US20080075702A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues 审中-公开
标题翻译：多能细胞和细胞系的雌激素或雄激素产生及其用于产生分化的细胞和组织的用途
公开(公告)号：US20080075702A1
公开(公告)日：2008-03-27
申请号：US11842026
申请日：2007-08-20
申请人： James Robl , Jose Cibelli , Amy Burnside
发明人： James Robl , Jose Cibelli , Amy Burnside
IPC分类号： A61K35/00 , A61P43/00 , C12N5/06 , C12Q1/02
CPC分类号： C12N5/0606 , A61K35/12 , A61K35/545 , C12N5/0696 , C12N15/873 , C12N2500/14 , C12N2501/999 , C12N2502/13 , C12N2506/04 , C12N2510/00 , C12N2517/10 , G01N33/5008 , G01N33/502 , G01N33/5044 , G01N33/5073 , G01N33/5088 , G01N2333/475
摘要： Methods for obtaining pluripotent (embryonic stem) cells from parthenogenetic embryos, especially primates, are provided. These cells are useful for producing differentiated cells, tissues and organs, especially human and non-human primate cells, tissues and organs.
摘要翻译：提供了从孤雌胚胎，特别是灵长类动物获得多能（胚胎干）细胞的方法。这些细胞可用于产生分化的细胞，组织和器官，特别是人和非人灵长类细胞，组织和器官。

88. 发明申请

US20080027106A1 METHODS OF TREATING PSYCHOSIS AND SCHIZPHRENIA BASED ON POLYMORPHISMS IN THE CNTF GENE 审中-公开
标题翻译：基于CNTF基因多态性的心理治疗和基因治疗方法
公开(公告)号：US20080027106A1
公开(公告)日：2008-01-31
申请号：US11754470
申请日：2007-05-29
申请人： Sridhar Kudaravalli , Mihael Polymeropoulos
发明人： Sridhar Kudaravalli , Mihael Polymeropoulos
IPC分类号： A61K31/445 , C07K16/00 , C12Q1/68
CPC分类号： G01N33/6896 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N2333/475 , G01N2800/302
摘要： This invention relates to the use of the association between the 103 G>A polymorphism in the CNTF gene to determine antipsychotic treatment strategies in patients with psychotic disorders.
摘要翻译：本发明涉及CNTF基因103G> A多态性之间关联的用途，以确定精神病患者的抗精神病药物治疗策略。

89. 发明授权

US07279289B2 Method of evaluating myelosuppressive state 有权
标题翻译：评估骨髓抑制状态的方法
公开(公告)号：US07279289B2
公开(公告)日：2007-10-09
申请号：US11225189
申请日：2005-09-14
申请人： Rosalyn D. Blumenthal , David M. Goldenberg
发明人： Rosalyn D. Blumenthal , David M. Goldenberg
IPC分类号： G01N33/53 , G01N33/567 , A61K38/19 , A61K38/20
CPC分类号： G01N33/6863 , G01N33/57488 , G01N2333/475 , G01N2800/24
摘要： The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose.
摘要翻译：本发明提供了用于评估患者骨髓抑制状态的试剂盒和方法。这些方法和试剂盒为细胞毒性和骨髓抑制治疗提供了有用的辅助物质。通过建立某些细胞因子的阈值水平作为骨髓抑制的替代物，治疗方案可以优化，以减少骨髓毒性，同时最大化有效剂量。

90. 发明申请

US20070026463A1 Compositions and methods of mutant Nogo-66 domain proteins 审中-公开
标题翻译：突变Nogo-66结构域蛋白的组成和方法
公开(公告)号：US20070026463A1
公开(公告)日：2007-02-01
申请号：US11495061
申请日：2006-07-28
申请人： Yuhong Xie , Brian Bates , Janet Paulsen
发明人： Yuhong Xie , Brian Bates , Janet Paulsen
IPC分类号： C40B30/06 , G01N33/53 , C07H21/04 , C12P21/06 , C07K14/705
CPC分类号： G01N33/566 , C07K14/47 , C07K2319/61 , G01N2333/475 , G01N2500/02
摘要： To facilitate the study of Nogo-66 interaction with its neuronal receptors, and to explore therapeutic opportunities, the present invention provides mutant human Nogo-66 domain-based proteins that do not aggregate during isolation or purification procedures, and methods for using these proteins. Aggregates of Nogo-66 domain containing proteins do not effectively or efficiently bind to the NgR1 receptor, and therefore limit the utility of Nogo-66 domain-based reagents. To overcome aggregation problems, the invention provides proteins that comprise a mutant human Nogo-66 domain, wherein the cysteine at position 47 of the wild-type human Nogo-66 domain is mutated. The invention also provides for various Nogo-66 domain fusion reporter proteins that are able to bind to NgR1, and therefore can be used in high-throughput assays to identify drug candidate compounds that can block binding of the Nogo-66 domain to NgR1, indicating that these compounds may be potential therapeutic agents for neurodegenerative diseases and neuronal repair.
摘要翻译：为了促进Nogo-66与其神经元受体的相互作用的研究，并且为了探索治疗机会，本发明提供了在分离或纯化过程中不聚合的突变型人Nogo-66结构域的蛋白质，以及使用这些蛋白质的方法。含有Nogo-66结构域的蛋白质的聚集体不能有效或有效地结合NgR1受体，因此限制了Nogo-66结构域的试剂的效用。为了克服聚集问题，本发明提供了包含突变人Nogo-66结构域的蛋白质，其中野生型人Nogo-66结构域的位置47处的半胱氨酸被突变。本发明还提供了能够结合NgR1的各种Nogo-66结构域融合报道蛋白，因此可用于高通量测定以鉴定可阻断Nogo-66结构域与NgR1结合的药物候选化合物，表明这些化合物可能是神经变性疾病和神经元修复的潜在治疗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式